Skip to content
  • About
    • Our Company
    • Team
    • Board of Directors
  • Research
    • Eosinophilic Esophagitis
    • APT-1011
    • FLUTE 3 Study
    • Pipeline
  • FLUTE 3 Study
  • Patients
    • Patient Advocacy Groups
    • Tools and Resources
  • News
    • Press Releases
  • Contact
Menu
  • About
    • Our Company
    • Team
    • Board of Directors
  • Research
    • Eosinophilic Esophagitis
    • APT-1011
    • FLUTE 3 Study
    • Pipeline
  • FLUTE 3 Study
  • Patients
    • Patient Advocacy Groups
    • Tools and Resources
  • News
    • Press Releases
  • Contact
  • About
    • Our Company
    • Team
    • Board of Directors
  • Research
    • Eosinophilic Esophagitis
    • APT-1011
    • FLUTE 3 Study
    • Pipeline
  • FLUTE 3 Study
  • Patients
    • Patient Advocacy Groups
    • Tools and Resources
  • News
    • Press Releases
  • Contact
Menu
  • About
    • Our Company
    • Team
    • Board of Directors
  • Research
    • Eosinophilic Esophagitis
    • APT-1011
    • FLUTE 3 Study
    • Pipeline
  • FLUTE 3 Study
  • Patients
    • Patient Advocacy Groups
    • Tools and Resources
  • News
    • Press Releases
  • Contact

Press Releases

  • February 27, 2023

Ellodi Pharmaceuticals Welcomes Debra Silberg MD, PhD, FACG to its Board of Directors

  • February 8, 2021

Ellodi Pharmaceuticals Announces Fast Track Designation Granted by the FDA to APT-1011 for the Treatment of Eosinophilic Esophagitis (EoE)

  • October 27, 2020

Ellodi Pharmaceuticals Announces Phase 2b Data Presented at ACG 2020 on the Safety and Efficacy of Maintenance Treatment Following Induction of Remission in Eosinophilic Esophagitis with APT-1011

  • October 21, 2020

Ellodi Pharmaceuticals Welcomes Dr. David Kessler and John Fraher to its Board of Directors

  • September 22, 2020

TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic Esophagitis

  • March 12, 2019

Primary End-Point achieved in Phase IIb Study (FLUTE™) for APT-1011

Ellodi Pharmaceuticals
325 Sentry Parkway
Building 5 West, Suite 200
Blue Bell, PA 19422

  • About
    • Our Company
    • Team
    • Board of Directors
  • Research
    • Eosinophilic Esophagitis
    • APT-1011
    • FLUTE 3 Study
    • Pipeline
  • FLUTE 3 Study
  • Patients
    • Patient Advocacy Groups
    • Tools and Resources
  • News
    • Press Releases
©2023 Ellodi Pharmaceuticals.  Privacy Policy  |  Cookie Policy  |  Terms & Conditions  |  EAP
  • About
    • Our Company
    • Team
    • Board of Directors
  • Research
    • Eosinophilic Esophagitis
    • APT-1011
    • FLUTE 3 Study
    • Pipeline
  • Patients
    • Patient Advocacy Groups
    • Tools and Resources
  • News
    • Press Releases

Ellodi Pharmaceuticals
325 Sentry Parkway
Building 5 West, Suite 200
Blue Bell, PA 19422

©2023 Ellodi Pharmaceuticals. 
Privacy Policy |
Cookie Policy |
Terms & Conditions | 
EAP

Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}

This link will take you to a site maintained by a third party who is solely responsible for the content of that site. Ellodi provides this link as a service to website visitors. Ellodi is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

 

Continue to Cancel
×